A Study Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects With MDS

This study is using a highly sensitive blood test — called MRD (minimal residual disease) testing — to personalize treatment decisions after stem cell transplantation in patients with certain blood cancers, including myelodysplastic syndromes (MDS). MRD tests can detect tiny amounts of cancer remaining in the body that normal tests miss. **You may be eligible if...** - You are 18 or older - You are eligible for a stem cell transplant - You have been diagnosed with MDS, mixed myelodysplastic/myeloproliferative syndrome, or AML with related changes and 20–29% blasts in the bone marrow - A traceable genetic abnormality has been identified in your cancer cells **You may NOT be eligible if...** - No identifiable genetic abnormality was found in your cancer cells (needed for MRD tracking) - You have uncontrolled high blood pressure, heart, liver, or kidney problems - You have psychiatric conditions or a language barrier that makes it difficult to understand what study participation involves Talk to your doctor to see if this trial is right for you.